Sagimet Biosciences Overview
Sagimet Biosciences (SGMT) has a P/E ratio of -8.24, below the sector sector average of 40.88.
Get informed when a big investor buys or sells
+ Follow-8.24
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
The latest P/E ratio for SGMT is -8.24. That is below the sector sector average of 40.88. Investors often review this figure alongside Sagimet Biosciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, SGMT currently prints -8.24 for P/E ratio, while the sector average sits near 40.88. That is roughly 120.2% below the sector mean. Large gaps often invite a closer look at Sagimet Biosciences's growth, margins, and balance sheet.
A P/E ratio of -8.24 for Sagimet Biosciences is not 'good' or 'bad' on its own. Compare it with the peer average (40.88) and with SGMT's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting SGMT's P/E ratio (-8.24), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
